Promising biological therapies for ulcerative colitis: A review of the literature

Table 2 Clinical trials evaluating the efficacy of Janus kinase inhibitor and integrin antagonists in ulcerative colitis patients

Drug	Trial	Study population	Protocol	Follow-up (wk)	Outcome
Tofacitinib	Sandborn et al[21]	31	0.5 mg po twice daily	8	32% (P = 0.39) clinical response at week 8
					13% (P = 0.76) clinical remission at week 8
		33	3 mg po twice daily	8	48% (P = 0.55) clinical response at week 8
					33% (P = 0.01) clinical remission at week 8
		33	10 mg po twice daily	8	61% (P = 0.10) clinical response at week 8
					48% (P < 0.001) clinical remission at week 8
		49	15 mg po twice daily	8	78% (P < 0.001) clinical response at week 8
					41% (P < 0.001) clinical remission at week 8
Vedolizumab	GEMINI 1[32]	225	300 mg iv at weeks 0, 2 and 6	6	47.1% (P < 0.001) clinical response at week 6
					16.9% (P = 0.00) clinical remission at week 6
		122	300 mg iv at week 0, 2, 6 and every 4 wk	52	44.8% (P < 0.001) clinical remission at week 52
		125	300 mg iv at week 0, 2, 6 and every 8 wk	52	41.8% (P < 0.001) clinical remission at week 52
Etrolizumab	Vermeire et al[35]	39	100 mg sc at week 0, 4 and 8	10	21% (P = 0.0040) clinical remission at week 10
		39	420 mg sc loading dose then 300 mg at week 2, 4, and 8	10	10% (P = 0.048) clinical remission at week 10

po: Perorally; iv: Intravenously; sc: Subcutaneously.